Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No increased cancer risk seen in long-term Lantus trial

This article was originally published in Scrip

Executive Summary

The longest, five-year, randomised controlled study comparing Sanofi-Aventis's long-acting, once-daily insulin analogue Lantus (insulin glargine) with human NPH (neutral protamine Hagedorn) insulin has not shown a higher incidence of cancer with Lantus, and similar effects on diabetic retinopathy, which the company hopes will quell some of the concerns raised by the recent publication of data from patient registries in several European countries that linked the blockbuster drug with a higher incidence of cancer ( June 30th, 2009).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts